The demand for contract development and manufacturing organisations (CDMOs) offering fill-finish and cold chain logistics services is on the rise. Driven by the COVID-19 pandemic, there is an increasing need for external partners to produce and distribute treatments and vaccines. CDMOs also face the challenge of adapting to the development and manufacture of new and more complex biologics, such as cell and gene therapies (C>s) and mRNA technologies. David King at Samsung Biologics discusses the challenges CDMOs face in meeting the growing global demand for high-capacity fill-finish and cold chain capabilities. Explaining how careful organisation and effective communication can support more successful drug programs, David offers his perspective on the strategies and tactics it takes to deliver a better program and patient outcomes.